Latest total liabilities for PRQR: $62M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
ProQR Therapeutics N.V posts a total liabilities of $62M as of March 2026. That compares with $73M in the prior-year period — down 15.5% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, ProQR Therapeutics N.V's total liabilities was $73M. The latest reading is $62M — a 15.5% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.
Total Liabilities is one piece of ProQR Therapeutics N.V's financial statement story. At $62M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for PRQR's total liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; ProQR Therapeutics N.V's other metric pages and overview cover the third.
Judging ProQR Therapeutics N.V against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total liabilities easier to interpret. Start with $62M here, then scan peer and history charts to see if the gap is persistent.